GlucoTrack Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 242/404 in the Biotechnology & Medical Research industry.Institutional ownership is high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GlucoTrack Inc's Score
Industry at a Glance
Industry Ranking
242 / 404
Overall Ranking
497 / 4562
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
GlucoTrack Inc Highlights
StrengthsRisks
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.00, at a high 3-year percentile range.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Ticker SymbolGCTK
CompanyGlucoTrack Inc
CEOGoode (Paul V)
Websitehttps://glucotrack.com/
FAQs
What is the current price of GlucoTrack Inc (GCTK)?
The current price of GlucoTrack Inc (GCTK) is 4.490.
What is the symbol of GlucoTrack Inc?
The ticker symbol of GlucoTrack Inc is GCTK.
What is the 52-week high of GlucoTrack Inc?
The 52-week high of GlucoTrack Inc is 468.000.
What is the 52-week low of GlucoTrack Inc?
The 52-week low of GlucoTrack Inc is 4.220.
What is the market capitalization of GlucoTrack Inc?
The market capitalization of GlucoTrack Inc is 4.04M.
What is the net income of GlucoTrack Inc?
The net income of GlucoTrack Inc is -22.60M.
Is GlucoTrack Inc (GCTK) currently rated as Buy, Hold, or Sell?
According to analysts, GlucoTrack Inc (GCTK) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of GlucoTrack Inc (GCTK)?
The Earnings Per Share (EPS TTM) of GlucoTrack Inc (GCTK) is -1335.127.